We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pronota Launches Protein Biomarker Verification Platform
Product News

Pronota Launches Protein Biomarker Verification Platform

Pronota Launches Protein Biomarker Verification Platform
Product News

Pronota Launches Protein Biomarker Verification Platform


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Pronota Launches Protein Biomarker Verification Platform"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Pronota nv has announced the launch of MASSterclass™, its protein biomarker verification tool, at the Molecular Medicine Tri-Conference in San Francisco.

The MASSterclass platform addresses a key bottleneck in biomarker development by enabling large-scale screening of biomarker candidates without the requirement to raise antibodies. The system raises the analytical bar for antibody-free protein assays by quantitating in the low nanogram per ml concentration range in blood plasma, thereby enabling measurement of proteins specific to disease or drug response.

The system incorporates a series of orthogonal complexity reduction steps combined with targeted tandem mass spectrometry to achieve required sensitivity levels while maintaining analytical reproducibility. The workflow also ensures that throughput is maintained when screening large panels of biomarker candidates by multiplexing different analytes in the same assay.

The platform complements MASStermind®, Pronota’s biomarker discovery platform capable of generating a high quality "hit list" of low-abundance protein biomarkers in blood. The combination of both platforms represents an integrated approach that can increase the chances of taking a biomarker from discovery through to clinical implementation within a practical timeframe.

"The introduction of MASSterclass represents an important milestone for Pronota", commented Nick McCooke, CEO. "The platform allows Pronota and our partners to bridge the gap between biomarker discovery and the final clinical assay through the efficient assessment and selection of the most promising candidates with the best clinical performance either alone or combined in panels".

Advertisement